Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2013 (2013), Article ID 383278, 6 pages
Clinical Study

Discrepancies between Antimullerian Hormone and Follicle Stimulating Hormone in Assisted Reproduction

1St. Michael’s Hospital, University Hospital Bristol NHS Foundation Trust, Southwell Street Bristol, BS2 8EG, UK
2University of Bristol, St. Michael's Hospital, Bristol BS2 8EG, UK
3Southmead Hospital, North Bristol NHS Trust & Bristol Centre for Reproductive Medicine Bristol, Southmead Road, Westbury-on-Trym, Bristol BS10 5NB, UK

Received 16 September 2013; Accepted 31 October 2013

Academic Editor: Enrique Hernandez

Copyright © 2013 Munawar Hussain et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Data from 107 women undergoing their first IVF/ICSI were analyzed. Relationships between antimullerian hormone (AMH) and follicle stimulating hormone (FSH) were analyzed after dividing patients into four groups according to AMH/FSH levels. Concordance was noted in 57% of women (both AMH/FSH either normal or abnormal) while 43%of women had discordant values (AMH/FSH one hormone normal and the other abnormal). Group 1 (AMH and FSH in normal range) and group 2 (normal AMH and high FSH) were younger compared to group 3 (low AMH and normal FSH) and group 4 (both AMH/FSH abnormal). Group 1 showing the best oocyte yield was compared to the remaining three groups. Groups 3 and 4 required higher dose of gonadotrophins for controlled ovarian hyperstimulation showing their low ovarian reserve. There was no difference in cycle cancellation, clinical pregnancy, and live birth/ongoing pregnancy rate in all groups. These tests are useful to predict ovarian response but whether AMH is a substantially better predictor is not yet established.